R. Wagman

发表

Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosis‡

C. Stehman-Breen, C. Critchlow, F. Xue, 2013, Pharmacoepidemiology and drug safety.

Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.

J. Reginster, P. Delmas, B. Mitlak, 2006, Bone.

Sustained Modeling‐Based Bone Formation During Adulthood in Cynomolgus Monkeys May Contribute to Continuous BMD Gains With Denosumab

P. Kostenuik, R. Baron, D. Dempster, 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis

Jacques P. Brown, D. Dempster, I. Valter, 2018, The Journal of clinical endocrinology and metabolism.

Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial.

J. S. San Martin, P. Miller, M. Peacock, 2011, The Journal of clinical endocrinology and metabolism.

Turnover : Six-Year Results of a Phase 2 Clinical Trial Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone

M. Peacock, M. McClung, E. Lewiecki, 2011 .

The use of teriparatide and PTH(1–84) for the treatment of osteoporosis

P. Miller, R. Wagman, 2006, Clinical Reviews in Bone and Mineral Metabolism.

Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis.

S. Silverman, Peiqi Chen, V. Piziak, 2005, The Journal of rheumatology.

Osteoporosis Associated with Pregnancy

R. Marcus, R. Wagman, 2013 .

CHAPTER 55 – Osteoporosis Associated with Pregnancy

R. Marcus, R. Wagman, 2008 .

Early Changes in Biochemical Markers of Bone Formation Predict BMD Response to Teriparatide in Postmenopausal Women With Osteoporosis

E. Lewiecki, A. Licata, Peiqi Chen, 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

The Ability of a Single BMD and Fracture History Assessment to Predict Fracture Over 25 Years in Postmenopausal Women: The Study of Osteoporotic Fractures

S. Cummings, J. Cauley, Dennis M Black, 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years.

N. Watts, N. Binkley, M. McClung, 2019, The Journal of clinical endocrinology and metabolism.

Reduction of Cortical Bone Turnover and Erosion Depth After 2 and 3 Years of Denosumab: Iliac Bone Histomorphometry in the FREEDOM Trial

D. Dempster, R. Chapurlat, P. Chavassieux, 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Effect of denosumab on fasting glucose in women with diabetes or prediabetes from the FREEDOM trial

E. Vittinghoff, A. Schwartz, N. Pannacciulli, 2018, Diabetes/metabolism research and reviews.

Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study

J. Adachi, S. Ferrari, Andrea T Wang, 2017, BMC Musculoskeletal Disorders.

Observations following discontinuation of long-term denosumab therapy

P. Miller, M. McClung, E. Lewiecki, 2017, Osteoporosis International.

Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension

Jacques P. Brown, N. Watts, E. Lewiecki, 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Effects of Up to 5 Years of Denosumab Treatment on Bone Histology and Histomorphometry: The FREEDOM Study Extension

Jacques P. Brown, I. Reid, P. Miller, 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial

P. Miller, M. Peacock, M. McClung, 2012, Osteoporosis International.

Relugolix Combination Therapy for Uterine Leiomyoma–Associated Pain in the LIBERTY Randomized Trials

A. Al-Hendy, E. Stewart, E. Hunsche, 2022, Obstetrics and gynecology.

Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study

R. Horne, D. Kendler, R. Wagman, 2014, Menopause.

Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2)

C. Becker, S. As-Sanie, M. Abrão, 2022, The Lancet.

SAT0479 Early Findings from Prolia® Post-Marketing Safety Surveillance for Atypical Femoral Fracture, Osteonecrosis of the Jaw, Severe Symptomatic Hypocalcemia, and Anaphylaxis

N. Watts, C. Stehman-Breen, S. Papapoulos, 2014 .

Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas

A. Al-Hendy, E. Stewart, R. Venturella, 2022, Obstetrics and gynecology.

Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.

A. Al-Hendy, E. Stewart, R. Venturella, 2021, The New England journal of medicine.

Modeling‐Based Bone Formation in the Human Femoral Neck in Subjects Treated With Denosumab

D. Dempster, M. Bostrom, N. Pannacciulli, 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Fracture incidence in a large cohort of men age 30 years and older with osteoporosis

C. O’Malley, P. Miller, U. Gruntmanis, 2015, Osteoporosis International.

A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial.

J. Reginster, E. Orwoll, P. Miller, 2015, The Journal of clinical endocrinology and metabolism.

The development of denosumab for the treatment of diseases of bone loss and cancer‐induced bone destruction

P. Kostenuik, W. Dougall, A. Braun, 2012, Annals of the New York Academy of Sciences.

A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density.

J. Reginster, S. Boonen, A. Grauer, 2012, The Journal of clinical endocrinology and metabolism.

Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate

C. Roux, J. Brown, C. Recknor, 2014, Osteoporosis International.

Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial

Jacques P. Brown, D. Kiel, R. Recker, 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

Jacques P. Brown, S. Cummings, J. Reginster, 2016, The Journal of clinical endocrinology and metabolism.

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

J. Reginster, C. Roux, E. Franek, 2015, Osteoporosis International.

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.

Jacques P. Brown, S. Cummings, J. Reginster, 2017, The lancet. Diabetes & endocrinology.

The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension

Jacques P. Brown, S. Cummings, E. Vittinghoff, 2013, The Journal of clinical endocrinology and metabolism.

Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies

Jacques P. Brown, I. Reid, J. S. San Martin, 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis

R. Rizzoli, J. Gallagher, J. Adachi, 2015, Climacteric : the journal of the International Menopause Society.

Discontinuation of Denosumab and Associated Fracture Incidence: Analysis From the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial

Jacques P. Brown, A. Grauer, C. Roux, 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.

Jacques P. Brown, L. Hofbauer, J. Wark, 2014, Bone.

Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.

P. Geusens, W. Lems, K. Saag, 2018, The lancet. Diabetes & endocrinology.

Further Nonvertebral Fracture Reduction Beyond 3 Years for up to 10 Years of Denosumab Treatment.

P. Miller, C. Roux, E. Lewiecki, 2019, The Journal of clinical endocrinology and metabolism.

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years

J. Reginster, C. O’Malley, J. Adachi, 2015, Osteoporosis International.

Denosumab Compared With Ibandronate in Postmenopausal Women Previously Treated With Bisphosphonate Therapy: A Randomized Open-Label Trial

C. Benhamou, N. Binkley, C. Recknor, 2013, Obstetrics and Gynecology.

Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) Study

D. Gold, S. Silverman, P. Miller, 2005, Osteoporosis International.

Bone remodeling in postmenopausal women who discontinued denosumab treatment: Off‐treatment biopsy study

Jacques P. Brown, A. Grauer, J. S. San Martin, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Extensive modeling-based bone formation after 2 months of romosozumab treatment: Results from the FRAME clinical trial

Jacques P. Brown, R. Chapurlat, P. Chavassieux, 2020 .

Eight years of denosumab treatment in postmenopausal women with osteoporosis: results from the first five years of the freedom extension

J. Reginster, C. Roux, E. Franek, 2014 .

Identifying fracture risk in postmenopausal women.

D. Black, R. Wagman, 2002, JAMA.

Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass

R. Horne, D. Gold, J. Borenstein, 2010, Osteoporosis International.

Ten years of Denosumab (DMAB) treatment in postmenopausal women with osteoporosis. Results from the FREEDOM Extension trial.

Jacques P. Brown, S. Cummings, J. Reginster, 2016 .

Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials.

A. Al-Hendy, E. Stewart, E. Hunsche, 2022, American journal of obstetrics and gynecology.

relationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 10 years of Denosumab (DMAB) treatment

Jacques P. Brown, J. Reginster, E. Lewiecki, 2016 .

Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial

J. S. San Martin, B. Clarke, J. Álvaro-Gracia, 2009 .

Fracture risk factors during treatment with denosumab

S. Cummings, E. Vittinghoff, L. Lui, 2013 .

The Ability of a Single BMD and Fracture History Assessment to Predict Fracture Over 25 Years in Postmenopausal Women: The Study of Osteoporotic Fractures

S. Cummings, J. Cauley, K. Ensrud, 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.

Jacques P. Brown, L. Hofbauer, J. Wark, 2014, Bone.

Relationship Between Bone Mineral Density T‐Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment

J. Reginster, E. Lewiecki, C. Libanati, 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Response to the Letter: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid.

S. Cummings, N. Pannacciulli, P. Miller, 2016, The Journal of clinical endocrinology and metabolism.